Scientific Evidence
An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus
Nov 2023
Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.
Publication: American Journal of Gastroenterology
A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus
Nov 2023
This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.
Publication: Clinical and Translational Gastroenterology
The Tissue Systems Pathology Test Outperforms Pathology Review in Risk-Stratifying Patients with Low-Grade Dysplasia
Nov 2023
This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.
Publication: Gastroenterology
A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center
Sep 2023
TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.
Publication: Poster presentation (61) at AFS 2023, Dallas
The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort
Aug 2023
This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.
Publication: Diseases of the Esophagus
Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies
Dec 2022
Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.
Publication: Clinical Gastroenterology and Hepatology
Spatialomics delivered to the clinic for improved health outcomes in Barrett’s esophagus
Dec 2022
The spatialomics approach of TissueCypher brings precision pathology to the clinic for more personalized care of patients with BE to improve outcomes.
Publication: The Journal of Precision Medicine
Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies
Dec 2022
Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.
Publication: Clinical Gastroenterology and Hepatology
Independent validation of TissueCypher to predict progression in community-based Barrett’s esophagus with low grade dysplasia: analysis in a completed prospective study (podium presentation at UEG 2020 annual meeting OP017)
Oct 2022
TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.
Publication: United European Gastroenterology Journal
An objective spatialomics test standardizes management decisions with potential to improve outcomes for Barrett’s esophagus patients
Oct 2022
This study evaluated the impact that variability in pathologic diagnosis has on patient care and shows how TissueCypher can aid in consistency of BE management.
Publication: Podium presentation (S386) at ACG 2022, Charlotte
An objective fully automated Barrett’s risk prediction assay outperforms most pathologists in risk stratifying Barrett’s esophagus with low-grade dysplasia
May 2022
Conventional pathology review based on histology has limitations, and the TissueCypher BE risk assessment tool can improve the accuracy of prognosis.
Publication: Podium presentation (695) at DDW 2022, San Diego
An objective fully-automated Barrett's risk prediction assay outperforms most pathologists in risk stratifying Barrett's esophagus with low-grade dysplasia
Apr 2022
Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.
Publication: Podium presentation (OP079) at ESGE 2022, Prague